Pneumothorax during lenvatinib treatment for hepatocellular carcinoma with lung metastasis
| Autor: | Yoichi Ishikawa, Nobuko Ishida, Makoto Hiroi, Masato Utsunomiya, Toyokazu Akimori, Michio Kuwahara, Yasuhiro Kawanishi |
|---|---|
| Rok vydání: | 2020 |
| Předmět: |
Oncology
Male Vascular Endothelial Growth Factor A medicine.medical_specialty Carcinoma Hepatocellular Lung Neoplasms Antineoplastic Agents 03 medical and health sciences chemistry.chemical_compound 0302 clinical medicine Japan Surgical oncology Internal medicine medicine Humans Thyroid cancer Protein Kinase Inhibitors Aged Lung business.industry Phenylurea Compounds Liver Neoplasms Gastroenterology Pneumothorax General Medicine respiratory system Hepatology medicine.disease respiratory tract diseases medicine.anatomical_structure chemistry 030220 oncology & carcinogenesis Hepatocellular carcinoma Quinolines 030211 gastroenterology & hepatology business Lenvatinib Tyrosine kinase |
| Zdroj: | Clinical journal of gastroenterology. 14(1) |
| ISSN: | 1865-7265 |
| Popis: | Lenvatinib is an inhibitor of tyrosine kinases, such as vascular endothelial growth factor receptor and fibroblast growth factor receptor, and was first approved for use in thyroid cancer in 2015 in Japan. Additional approval was given in March 2018 for its use as a first-line treatment for advanced or unresectable hepatocellular carcinoma. Herein, we report a case of pneumothorax during lenvatinib treatment for multiple lung metastases of hepatocellular carcinoma in a 71-year-old man. Although the development of pneumothorax during treatment with anticancer agents for lung metastases is well-known, this is the first report of pneumothorax induced by lenvatinib during treatment for lung metastases of hepatocellular carcinoma. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full text from SpringerLink